New aTyr Class Action Expands Investor Window After EFZO-FIT Failure
A freshly filed complaint broadens the alleged class period to November 2024 through September 2025, sharpening focus on the December 8 lead‑plaintiff deadline.
Overview
- Hagens Berman filed King v. aTyr Pharma in the Southern District of California, seeking to represent investors who bought shares from Nov. 7, 2024 to Sept. 12, 2025.
- Multiple shareholder firms, including Rosen, Glancy Prongay & Murray, The Gross Law Firm, Levi & Korsinsky, and the Law Offices of Howard G. Smith, continue to solicit investors ahead of the Dec. 8, 2025 motion deadline.
- Complaints allege aTyr made materially misleading statements about efzofitimod’s efficacy, emphasizing claims that patients could completely taper steroid use and presenting an unduly favorable study narrative.
- The suits follow a Sept. 15, 2025 disclosure that Phase 3 EFZO-FIT did not meet its primary endpoint on oral corticosteroid reduction, after which aTyr shares fell about 83.2% to close at $1.02.
- aTyr has said it will consult the FDA on next steps for efzofitimod, and no class has been certified as the litigation remains in early stages.